Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Shattuck Labs, Inc.NASDAQ: STTK

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 12607.2 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
100.0%+85.5 pp YoY
LTMMar 2026
-82.0%-120.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+85.5 pp——
3 years+12607.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+85.5pp

Gross Margin vs competitors

How STTK compares with its peers on the latest reported figures

  • STTK's LTM Mar 2026 gross margin of -82.0% is the lowest of the 6 companies compared; the peer median is 99.5%.
  • Its year-over-year change of -120.1 pp is the lowest of 3, against a peer median of +12.7 pp.
  • Over three fiscal years its change of +12607.2 pp compares with a peer median of -0.7 pp.
STTK Competitors Peer median
Gross Margin for STTK and competitors
Company Period LTM level YoY 3-year change
FTHFaeth Therapeutics, Inc.LTM Jun 20262740.8% ——
CBIOCrescent Biopharma, Inc.LTM Mar 2026100.0% —+0.0 pp
BDTXBlack Diamond Therapeutics, Inc.FY202599.5% ——
PBYIPuma Biotechnology, Inc.LTM Mar 202674.5% +2.1 pp-1.3 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 202653.2% +23.4 pp—
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
INDPIndaptus Therapeutics, Inc.FY2025— ——
PDSBPDS Biotechnology CorporationFY2025— ——
NBPNovaBridge BiosciencesFY2025— ——
Peer median (excluding STTK) 99.5%+12.7 pp-0.7 pp

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.